A Review on Diabetic Peripheral Neuropathy

Abstract

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes affecting over 90% of the diabetic patients. Due to the toxic effects of hyperglycemia there is development of this complication. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. Hence DPN is often inadequately treated, and the role of improving glycaemic control in diabetes. Major international clinical guidelines for the management of DPN recommend several symptomatic treatments. First-line therapies include tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, and anti-consultants that act on calcium channels. Other therapies include opioids and topical agents such as capsaicin and lidocaine. The objectives of this paper are to review current guidelines for the pharmacological management of DPN.
 Keywords: DPN, hyperglycemia, depression, lidocaine

The Effect of Educational Program on Pain Management, Self-Efficacy Behavior, and Quality of Life among Adult Diabetic Patients with Peripheral Neuropathy Pain: A Randomized Controlled Trial

“…The educational program was specially designed for adult patients with PDPN. The program was structured and adopted by the authors after a review of the relevant literature [7,15,26,27]. The educational program was structured with the following information: ▪ DM and PDPN.…”

“…One of the most relevant complications of T2DM is painful diabetic peripheral neuropathy (PDPN) 2 4 6 . Clinically, PDPN is defined as pain that is a direct consequence of abnormalities in the peripheral somatosensory system in individuals with diabetes; the most common manifestation of the pain could be burning, aching, or shooting in nature 4 6 7 . In the UK, the estimated incidence of PDPN was 15.3 cases per 100 000 individual years in the primary care population in 2002 and this increased to 27.2 cases per 100 000 individuals in 2005 4 6 7 .…”

“…Clinically, PDPN is defined as pain that is a direct consequence of abnormalities in the peripheral somatosensory system in individuals with diabetes; the most common manifestation of the pain could be burning, aching, or shooting in nature 4 6 7 . In the UK, the estimated incidence of PDPN was 15.3 cases per 100 000 individual years in the primary care population in 2002 and this increased to 27.2 cases per 100 000 individuals in 2005 4 6 7 . Roughly, more than 11% of patients with diabetic peripheral neuropathy (DPN) worldwide are suffering from PDPN 6 7 .…”

“…In the UK, the estimated incidence of PDPN was 15.3 cases per 100 000 individual years in the primary care population in 2002 and this increased to 27.2 cases per 100 000 individuals in 2005 4 6 7 . Roughly, more than 11% of patients with diabetic peripheral neuropathy (DPN) worldwide are suffering from PDPN 6 7 .…”

Prevalence and correlates of vibration perception threshold based diabetic peripheral neuropathy in Gujarati urban population: A cross sectional study

“…Same can be objectively measured, quantified, and graded by vibration perception threshold (VPT). [ 4 ] In light of lack of VPT-based DPN study,[ 5 ] we intended for the same in our population.…”